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Summary
Background Topical steroids are the first choice for the treatment of oral lichen pla-
nus (OLP). Antifungal drugs are often employed together with them, to prevent
secondary oral candidosis, although it has been suggested anecdotally that they
can also be beneficial for OLP itself.
Objectives To compare the effect of clobetasol propionate with and without a top-
ical antifungal drug (miconazole) on the symptoms and extension of OLP.
Methods A randomized, parallel, double-blind trial was conducted at the Unit of
Oral Medicine and Pathology of the University of Milan. Thirty-five outpatients
with histologically proven OLP were randomly assigned to receive either clobeta-
sol propionate and miconazole, or clobetasol propionate and placebo for
6 weeks. Primary outcomes included symptoms and extension of lesions; adverse
effects were also recorded.
Results All the patients who concluded the study (30 of 35) showed clinical and
subjective improvement within 3 weeks. The addition of miconazole did not
affect in a significant way the signs and symptoms of OLP. No cases of clinical
candidosis were seen in the patients taking miconazole, while one-third (five of
15) of the placebo group were affected.
Conclusions Although effective in preventing iatrogenic candidosis, the addition
of miconazole to topical steroid treatment does not improve the efficacy of
the therapy.
Oral lichen planus (OLP) is a chronic inflammatory condi-
tion affecting the oral mucous membranes of 0Æ1–4% of
the population.1 OLP is often asymptomatic, but in some
patients, mainly those affected by the atrophic-erosive form,
can cause symptoms ranging from burning sensation to
severe pain, sometimes interfering with speaking, eating and
swallowing.1,2 Because the precise aetiological agents of this
condition remain unknown, the treatment of OLP is focused
mainly on reducing symptoms, through modulation of local
immune response. To this aim topical corticosteroids are
considered the first-choice drugs and good evidence indi-
cates that among them clobetasol propionate is probably the
most effective.3,4 Second-choice drugs, to be employed in
unresponding cases, include systemic steroids,5 aminosalicy-
lates,6 retinoids7 and local immunomodulating agents, such
as ciclosporin8,9 or the newly available tacrolimus10 or
pimecrolimus.11
To prevent oral candidosis, a consequence of local immuno-
suppressive drugs, an antifungal drug is often associated with
topical corticosteroids;3 however, no sound data are available
on the frequency of such adverse effects. In addition, it is not
known whether topical antifungal drugs, besides preventing
oral candidosis, can also improve the efficacy of steroidal
treatment, in terms of clinical outcomes such as symptoms or
extension of the lesion.12,13
The aim of this randomized clinical trial was to compare
the efficacy of topically applied clobetasol propionate with and
without a topical antifungal drug (miconazole) in the treat-
ment of patients with symptomatic OLP.
Patients and methods
Setting and participants
The study was conducted at the Oral Medicine Unit of the
Dental School of the Universita` degli Studi di Milano (Italy), a
unit accessible by patients both directly and by referral from
dental or medical practitioners. Eligible patients had to meet
the following criteria: (i) clinical and histological diagnosis of
OLP; (ii) symptomatic form of the disease; and (iii) age over
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18 years. Subjects were excluded from the study in the case of
(i) previous treatment for OLP; (ii) systemic or local treatment
with antifungal or corticosteroids in the 6 months prior to the
study; (iii) hypersensitivity to clobetasol propionate or micon-
azole; or (iv) uncontrolled diabetes or hypertension, systemic
conditions that could hamper participation and compliance
with the study.
Randomization
Every new patient seen at the Oral Medicine Unit who met
the eligibility criteria was asked to enter the trial. After
being informed about the scope and methods of the study,
the subjects who accepted signed the written informed con-
sent form, and then were randomly allocated to one of the
two arms of the study (test group or control group). The
random allocation sequence was generated using software
available online at http://graphpad.com/quickcalcs/randomize1.
cfm (accessed 26 January 2007). To guarantee the allocation
concealment, the sequence was hidden from the researchers
determining patient eligibility, and assignment to one of
the two arms was performed by a researcher who was not
involved in enrolment.
Interventions, outcomes and blinding
Following randomization, two 30-mL syringes were given to
every patient. One, labelled with the letter A, contained clo-
betasol propionate gel, the other labelled with the letter B,
contained miconazole 2% gel (test group) or placebo (control
group). Neither the patient nor the clinician was aware of the
content of the syringes marked with the letter B, which were
indistinguishable (double-blind design).
The clobetasol propionate gel was prepared by one of the
authors (D.D.B.) in the hospital pharmacy, following the indi-
cations of Good Manufacturing Practice [Food and Drug
Administration, U.S.A.; http://www.fda.gov/cdrh/devadvice/
32.html (accessed 1 February 2007)] and the Italian pharma-
copoeia, according to the following recipe: 0Æ5 g clobetasol
propionate, 40 g hydroxyethyl cellulose, 20 mL alcohol
(96 C), 934 mL water, 20 mL methyl-parahydroxi-benzoate
alcohol solution [prepared with 20 mL of alcohol (96 C) and
2 g methyl-parahydroxi-benzoate]. As antifungal gel, a com-
mercially available miconazole 2% preparation (Micotef oral
gel; Teofarma, Valle Salimbene, Pavia, Italy) was employed.
The placebo was prepared as an inactive gel.
To make use more convenient and assuring blindness, the
gels were put into syringes with a screw plug.
Patients were instructed to apply the gel from syringe A
(clobetasol propionate) twice daily and gel from syringe B
(miconazole or placebo) once daily. Written instructions
suggested applying the gel on dry mucosae and to avoid
food and drink for 1 h following application. All patients
were provided with a phone number to contact one of
the researchers in case of problems or to get new doses
of gel.
During the first visit (t0) and the two control visits, one
after 3 weeks (t21) and another after 6 weeks (t42), the mouth
of every patient was carefully inspected, photographed and
the following variables were recorded: (i) oral symptoms,
registered by means of a visual analogue scale (VAS) of
10 cm, horizontal line marked 0 (no pain) to 10 (the worst
pain ever experienced); and (ii) extension of the OLP lesions,
measured as a percentage on the basis of a 50 site per mouth
scheme (2% for each site). During control visits (t21 and t42)
the patients were asked explicitly about the occurrence of
adverse events.
To measure Candida carriage, mouth swills, using 10 mL
sterile distilled water were collected from each patient
and 1 mL was cultured on caffeic acid–ferric citrate agar
[Sabouraud’s dextrose agar containing chloramphenicol (10
lL L)1)]. After 48-h incubation at 37 C, colony forming
units (cfu) per mL of mouth swill were counted.14 To control
compliance the syringes were weighed before starting and at
each control visit.
Statistical methods
Fisher’s exact test or the v2 test were used to compare
binomial variables, paired or unpaired two-tailed t-test for
continuous variables.
Results
Patients
Forty patients who visited in the clinic of the Oral Medicine
Unit of the Dental School of the Universita` degli Studi di
Milano (Italy) because of symptomatic OLP were assessed for
eligibility. Two patients were excluded because of systemic
conditions, in particular uncontrolled diabetes (n ¼ 1) and
uncontrolled hypertension (n ¼ 1), and three because we con-
sidered their symptoms too mild to need treatment. All the
patients meeting the inclusion criteria agreed to participate in
the study. Thirty-five patients were enrolled in the study and
were randomly allocated in one of the two groups: 18 were
assigned to the test group (clobetasol propionate + miconaz-
ole) and 17 to control group B (clobetasol propionate + pla-
cebo). Patient characteristics are summarized in Table 1. The
characteristics of the two groups did not show statistically
significant differences; only VAS was at the limit of statistical
significance (P ¼ 0Æ0518).
Five patients did not complete the trial, three from the test
group and two from the control group. Among those of the
test group, two were excluded because, having finished all the
gel of syringe A, instead of contacting the researchers and ask-
ing for a new dose, as recommended, suspended the treat-
ment, and two patients did not attend control visits for
personal reasons. Among those of the control group, one
developed a papilloma on the tongue and asked to be exclud-
ed, and one did not attend the control visits, without inform-
ing us of the reason (Fig. 1).
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Outcomes
At the end of the study, the two groups had used similar
amounts of gel from syringe A (test group, 28Æ93 g; control
group, 33Æ07 g; P ¼ 0Æ4949) and syringe B (test group,
16Æ27 g; control group, 19Æ87 g; P ¼ 0Æ3071). Oral symp-
toms improved significantly in both groups. As shown in
Figure 2 the improvement was for the most part in the first
3 weeks of treatment, while in the following 3 weeks the
symptoms decreased less dramatically. The statistical analy-
sis confirmed the clinical impression (Fig. 3), in fact in
both groups the comparison between pain (measured as
mean VAS) at baseline and first control was highly signifi-
cant (P ¼ 0Æ0020 in the test group and P < 0Æ0001 in the
control group), while between the first and second control
visits the mean VAS did not change significantly (P ¼
0Æ0718 in the test group and P ¼ 0Æ0833 in the control
group).
Miconazole did not affect the efficacy of treatment: the
comparison of mean VAS between the test and control groups
Excluded (n = 5)
Not meeting inclusion criteria (n = 2)
Refused to participate (n = 0)
Other reasons (n = 3)
Analysed (n = 15)
Excluded from analysis (n = 0)
Lost to follow-up (n = 1)
Discontinued intervention (n = 2)
Reasons: run out of gel A 
Allocated to intervention
(n = 18)
Received allocated intervention
(n = 18)
Did not receive allocated intervention
(n = 0)
Lost to follow-up (n = 0) 
Discontinued intervention (n = 2)
Reasons: papilloma
personal reasons
Enrolment
Is it randomized?
Allocated to intervention
(n = 17)
Received allocated intervention
(n = 17)
Did not receive allocated intervention
(n = 0)
Follow-up
Allocation
Analysed (n = 15)
Excluded from analysis (n = 0)
Assessed for eligibility (n = 40)
Analysis Fig 1. Flow of participants through each
stage (consort flowchart).
Table 1 Characteristics of the subjects
enrolled in the study, following
randomization in the two groups
Test group
(n ¼ 18)
Control group B
(n ¼ 17)
Total
(n ¼ 35)
Female 11 13 24
Male 7 4 11
Mean age, years
(SD)
60Æ7 (11Æ8) 64Æ9 (9Æ9) 62Æ7 (11Æ0)
Mean VAS (SD) 4Æ7 (2Æ3) 6Æ2 (2Æ4) 5Æ4 (2Æ4)
Mean lesion
extension (SD), %
26Æ6 (3Æ0) 29Æ9 (20Æ1) 28Æ2 (17Æ0)
Positive Candida
cultures
9 7 16
HCV status 4 positive 5 positive 9 positive
4 negative 4 negative 8 negative
3 unknown 8 unknown 18 unknown
HCV, hepatitis C virus; VAS, visual analogue score.
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showed no difference, either at first (P ¼ 0Æ5587) or second
control visits (P ¼ 0Æ0833).
Lesion extension showed similar response (Fig. 4). Both
groups demonstrated a significant decrease of lesions during
the first 3 weeks (P ¼ 0Æ0089 in the test group and P ¼
0Æ0005 in the control group), followed by a less marked
improvement in the following 3 weeks (P ¼ 0Æ0918 in the
test group and P ¼ 0Æ1089 in the control group). Again,
patients treated with clobetasol propionate and miconazole did
not show better results in terms of lesion reduction; the com-
parison of mean extension between the test group and the
control group showed no difference, either at the first (P ¼
0Æ2367) or second control visit (P ¼ 0Æ1819).
Candida carriage, in terms of cfu, was similar in the two
groups during the whole study (Table 2). The only notable
difference was seen during the second control visit when the
control group showed a higher number of patients with cfu
> 100 compared with the test group (27% vs. 0%). As expect-
ed, no cases of clinical candidosis were seen in the test
group, while one-third of the control group were affected
during the second control visit; this difference was statistically
significant by two-tailed Fisher’s exact test (P ¼ 0Æ0421). Four
of the patients who developed candidosis had a pseudomem-
branous form and high cfu (three > 1000 and one ¼ 700) at
Pain (VAS) test group
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Fig 2. Modification of pain, as recorded by visual analogue scale
(VAS), along the 6 weeks of treatment, in the two groups of the study.
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Fig 3. Comparison of the oral symptoms between the two groups
and in the same group along the study. VAS, visual analogue scale.
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Fig 4. Comparison of the extension of the lesions between the two
groups and in the same group along the study.
Table 2 Comparison of Candida carriage and candidosis incidence between the two groups
Test group (n ¼ 15) Control group (n ¼ 15)
Baseline First control Second control Baseline First control Second control
Growth/no growtha 9/6 5/10 7/8 7/8 8/7 7/8
cfu mL)1 > 100/cfu mL)1 < 100 1/14 0/15 5/10 0/15 4/11 5/10
Clinical signs of candidosis 0/15 0/15 0/15 0/15 0/15 5b/10
aNumber of patients from whose oral cavities Candida spp. were isolated (growth/no growth). bFour pseudomembranous candidosis and one
angular cheilitis.
cfu, colony-forming units.
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the first control visit, the fifth developed angular cheilitis, hav-
ing negative Candida culture throughout. To verify whether the
presence of positive Candida carriage could predict the onset of
candidosis in patients without antifungal prophylaxis, we cal-
culated the predictive value of a positive Candida carriage for
candidosis onset. The negative predictive value was 0Æ875
(95% CI 0Æ4735–0Æ9968) and positive predictive value was
0Æ571 (95% CI 0Æ1841–0Æ9010), meaning that in the case of
negative carriage, more than 80% of patients will not develop
candidosis, while in the case of a positive test, about half of
the patients will develop the condition.
Discussion
In the present randomized controlled trial, we tested the
hypothesis that adding an antifungal drug (miconazole) to a
topical treatment with a steroid (clobetasol propionate) may
improve the treatment of patients affected by symptomatic
OLP. The clobetasol propionate gel showed good efficacy in
the treatment of OLP. The addition of miconazole did not
improve the outcomes considered, although it prevented the
onset of candidosis secondary to local immunosuppression.
The beneficial effects of topical steroids for patients affect-
ed by OLP are consistent with the results documented by a
number of clinical trials of different methodological quality.
In particular, clobetasol propionate in aqueous solution, oint-
ment or orabase, has been shown to be effective in com-
parative and placebo-controlled studies.2 What this study
adds to our knowledge on the treatment of OLP with topical
steroids is that most of the beneficial effects are reached
within the first 3 weeks; consequently this may be proposed
as the standard duration of the initial treatment at full dos-
age, which may be followed by a progressive decrease of
the drug until a maintenance dose is found or therapy can
be suspended. It must be stressed that in the case of topical
treatment, dosage refers to frequency of applications, as the
amount of drug depends on the extent of lesions. Unlike
other studies reporting complete remission in up to 75% of
patients,9 we did not record any such cases (i.e. complete
symptomatic and clinical resolution). This may be due to the
length of our study (6 weeks), which was shorter compared
with similar studies, the definition of complete remission,
differences in patient population, delivery system,4 or some
other unrecognized factor. At the end of the present study
all patients of both groups continued topical steroid treat-
ment with different modalities and in some cases a different
drug (betamethasone mouthwash).
According to our results, the addition of an antifungal to
OLP treatment with topical steroids does not improve outcomes
such as pain and extension of the lesions. However, as was eas-
ily predictable, it prevented candidosis, which affected patients
of the control group only. What we could not predict, as it was
documented only occasionally before,15,16 was the incidence of
complications with such topical steroid treatment. Among sub-
jects not receiving antifungal prophylaxis, candidosis developed
in 30% of patients. As steroid treatment in OLP patients can last
for months or years, prolonged antifungal treatment may not
be indicated. On the basis of the negative predictive value of
Candida carriage that we found (0Æ875 95% CI 0Æ4735–0Æ9968),
it is possible to avoid antifungal prophylaxis in patients with
negative Candida carriage before starting treatment, employing
instead a local anti-infective agent with weak antifungal effect,
such as a 0Æ12% chlorhexidine mouthwash.
In conclusion, topical clobetasol propionate gel is an effect-
ive treatment for symptomatic OLP, able to significantly
improve symptoms and extension of the lesions within
3 weeks. About 30% of patients undergoing such treatment
can develop oral candidosis whether or not an antifungal drug
is employed; however, prophylaxis with such a drug may not
be indicated in subjects with negative Candida carriage before
starting treatment.
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